Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company developing precisely targeted kinase inhibitors for oncogene-driven cancers, with a focus on non-small cell lung cancer (NSCLC). The NUVL news feed on Stock Titan aggregates company announcements, press releases, and related coverage so readers can follow how its pipeline and regulatory interactions progress over time.
According to Nuvalent’s disclosures, its lead investigational programs include zidesamtinib, a ROS1-selective inhibitor for ROS1-positive NSCLC, and neladalkib, an ALK-selective inhibitor for ALK-positive NSCLC. News items often highlight pivotal and preliminary data from the ARROS-1 and ALKOVE-1 Phase 1/2 trials, updates on the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC, and information about design features such as brain penetrance and activity against resistance mutations.
Investors and observers can also find coverage of Nuvalent’s regulatory milestones, including FDA breakthrough therapy and orphan drug designations, New Drug Application (NDA) submissions and acceptances, and PDUFA target action dates. Corporate developments such as public equity offerings, cash runway guidance, royalty arrangements on future net sales of zidesamtinib and neladalkib, and board appointments are regularly disclosed through press releases and Form 8-K filings and are reflected in the news flow.
For those tracking NUVL, this news stream provides a centralized view of clinical trial readouts, conference presentations, financing activities, and strategic updates that shape the company’s outlook in targeted oncology. Bookmarking the NUVL news page on Stock Titan can help readers quickly review new disclosures and place them in the context of Nuvalent’s broader development strategy.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming UBS 2025 Virtual Oncology Day. The company's CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat on October 1, 2025, at 3:30 p.m. ET.
Investors can access the live webcast through Nuvalent's website investor section, where it will remain available for 30 days after the presentation.
Nuvalent (Nasdaq: NUVL) presented pivotal data for zidesamtinib, its novel ROS1-selective inhibitor, for treating TKI pre-treated patients with advanced ROS1-positive NSCLC at WCLC 2025. The data, initially announced in June 2025, supports the company's ongoing rolling NDA submission to the FDA.
The FDA has accepted the NDA for the Real-Time Oncology Review (RTOR) program, enabling earlier submission of efficacy and safety results. Nuvalent expects to complete the rolling NDA submission in Q3 2025 and is exploring potential line-agnostic expansion opportunities with the FDA.
The drug aims to address unmet needs in ROS1-positive NSCLC patients, particularly those intolerant to current TKIs or experiencing disease progression with brain metastases or resistance mutations.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.
Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.
Nuvalent (Nasdaq: NUVL) announced that pivotal data from their ARROS-1 Phase 1/2 clinical trial for zidesamtinib, their novel ROS1-selective inhibitor, will be presented at the WCLC 2025 Presidential Symposium in Barcelona. The presentation will showcase results for both TKI pre-treated and TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer (NSCLC).
The company has initiated a rolling NDA submission for zidesamtinib in TKI pre-treated patients, with FDA accepting it under the Real-Time Oncology Review (RTOR) pilot program. Nuvalent targets completion of the NDA submission in Q3 2025 and is exploring potential line-agnostic expansion opportunities with the FDA.
Nuvalent (Nasdaq: NUVL) reported significant pipeline progress and Q2 2025 financial results. The company initiated a rolling NDA submission for zidesamtinib for ROS1-positive NSCLC treatment, targeting completion in Q3 2025. They also launched the ALKAZAR Phase 3 trial of neladalkib for front-line ALK-positive NSCLC.
Key developments include the promotion of Jason Waters to SVP, Commercial and appointment of Christy Oliger to the board. The company maintains a strong financial position with $1.0 billion in cash as of June 30, 2025, expected to fund operations into 2028. Q2 2025 financial results showed R&D expenses of $80.9M, G&A expenses of $23.7M, and a net loss of $99.7M.
Upcoming milestones include topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025 and preliminary data presentation at ESMO Congress 2025 for ALK-positive solid tumors beyond NSCLC.
Nuvalent (NASDAQ: NUVL) has initiated ALKAZAR, a global Phase 3 randomized controlled trial evaluating neladalkib for treatment-naive patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The study will compare neladalkib against ALECENSA® (alectinib), a current front-line standard treatment.
The trial will enroll approximately 450 TKI-naïve patients, randomized 1:1 to receive either neladalkib or alectinib monotherapy. The primary endpoint is progression-free survival (PFS), with multiple secondary endpoints including overall survival and intracranial response measures.
Neladalkib is also being evaluated in the ALKOVE-1 Phase 1/2 trial, where Phase 1 data showed durable clinical responses in heavily pre-treated patients, including those with brain metastases and resistance mutations. Topline pivotal data from ALKOVE-1's Phase 2 portion is expected by year-end 2025.
Nuvalent (NASDAQ:NUVL) announced positive pivotal data from the ARROS-1 clinical trial of zidesamtinib for ROS1-positive NSCLC patients. The drug showed an overall response rate (ORR) of 44% in 117 TKI pre-treated patients, with 78% durability at 12 months. In patients treated with one prior ROS1 TKI, the ORR increased to 51% with 93% durability at both 12 and 18 months.
The company has aligned with FDA on NDA submission strategy and plans to initiate a rolling NDA submission in July 2025, targeting completion in Q3 2025. Zidesamtinib demonstrated strong intracranial responses, effectiveness against ROS1 G2032R resistance mutation, and a well-tolerated safety profile with only 10% dose reduction and 2% discontinuation rates.
Nuvalent (NASDAQ: NUVL) has announced it will host a webcast and conference call on June 24, 2025, at 8:00 AM ET to present pivotal data from their ARROS-1 Phase 1/2 clinical trial. The presentation will focus on zidesamtinib, their novel ROS1-selective inhibitor, specifically its performance in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer.
The event will be accessible via phone and live video webcast through the company's investor relations website, with presentation slides available. A replay will be archived for 30 days following the presentation.